Company news

Moleculin Biotech, Inc. news in 2020

Moleculin Biotech, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

December 28, 2020

Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases

December 16, 2020

Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference

December 2, 2020

Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066

November 30, 2020

Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML

November 18, 2020

Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020

November 12, 2020

Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19

October 28, 2020

Moleculin Announces Independent Study Validates Annamycin's Ability to Target Lung Localized Tumors

October 20, 2020

Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial

October 12, 2020

Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV

October 5, 2020

Moleculin Appoints Elizabeth Cermak to Board of Directors

October 4, 2020

Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University

September 30, 2020

Moleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 Virus for New Antimetabolites

September 28, 2020

Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122

September 13, 2020

Moleculin Announces Successful Completion of Pre-IND Meeting with the FDA

September 8, 2020

Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020

August 11, 2020

Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate

July 14, 2020

Moleculin Provides Update on Annamycin Clinical Development

July 1, 2020

Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases

June 24, 2020

Moleculin Announces Confirmatory In Vitro Analysis of WP1122

June 15, 2020

Moleculin Announces Submission to Expand Clinical Sites in European AML Trial

June 3, 2020

Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment

June 1, 2020

Moleculin Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

May 26, 2020

Moleculin Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 15, 2020

May 7, 2020

Moleculin Approved to Accelerate European Clinical Trial

April 27, 2020

Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team

April 21, 2020

Moleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus Testing

April 19, 2020

Moleculin Announces Leading Virologist Joins Development Team

April 14, 2020

Moleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100%

April 7, 2020

Moleculin Announces Additional Positive Safety Data in EU AML Trial

April 1, 2020

Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate

March 19, 2020

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2019

March 18, 2020

Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus

March 16, 2020

Moleculin Announces Dr. Hongbo Zhai Joins Science Advisory Board

March 9, 2020

Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date

February 19, 2020

Moleculin Announces $6.0 Million Registered Direct Offering

February 5, 2020

Moleculin to Seek Accelerated FDA Approval and Plans for Pivotal Phase 2 AML Trial

February 4, 2020

Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin

February 2, 2020

Decks in 2020